Table 2.
Characteristics and supportive therapies used with ICU-AAV patients
| Length of stay (days) | 7.0 (4.5–17.5) |
|---|---|
| Reasons for ICU admission, n (%) | |
| Respiratory failure | 44 (45.4) |
| And renal failure | 23 (23.7) |
| And neurological failure | 1 (1.0) |
| Acute renal failure | 17 (17.5) |
| And neurological failure | 4 (4.1) |
| Neurological failure | 4 (4.1) |
| Heart failure | 3 (3.1) |
| Hemorrhagic shock | 1 (1.0) |
| SOFA (at admission) | 6 (4.0–9.0) |
| SAPS II | 39.0 (31.0–51.0) |
| Respiratory assistance, n (%) | |
| Mechanical ventilation | |
| Invasive or/and noninvasive | 66 (68.0) |
| Within 48 h of admission | 58 (59.8) |
| Noninvasive ventilation only | 19 (19.6) |
| Invasive ventilation only | 36 (37.1) |
| Noninvasive and invasive ventilation | 11 (11.3) |
| Length of respiratory assistance (days) | 10.0 (5.5–18.5) |
| PaO2/FiO2 | 92.0 (58.8–182.0) |
| Kidney involvement | |
| Serum creatinine at admission, (μmol/L) | 256.5 (115.3–527.8) |
| Maximum serum creatinine in ICU, (μmol/L) | 348.0 (160.0–673.0) |
| AKIN score ≥1, n (%) | 89 (91.8) |
| Renal replacement therapy, n (%) | 55 (56.7) |
| Within 48 h of admission | 34 (35.1) |
| Hemodynamic assistance | |
| Vasopressive amines, n (%) | 26 (26.8) |
| Within 48 h | 25 (25.8) |
| Length of treatment (days) | 6.0 (3–11.5) |
| Infectious events | |
| Early/late* | 29/10 |
| Lung infection, n (%) | 29 (74.4)** |
| Other sites, n (%) | 10 (25.6)** |
| Patients with pathogen identified, n (%) | 32 (82.1)** |
* Diagnosed < or >48 h after ICU admission
**Among patients that experienced infection